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Bone remodeling is performed by osteoclasts
and osteoblasts at the bone surface. Inside
of bone is a network of numerous osteocytes,
whose specific function has remainedanenigma.
Here we describe a transgenic mouse model in
which inducible and specific ablation of osteo-
cytes is achieved in vivo through targeted
expression of diphtheria toxin (DT) receptor. Fol-
lowing a single injection of DT, approximately
70%–80% of the osteocytes, but apparently
no osteoblasts, were killed. Osteocyte-ablated
mice exhibited fragile bone with intracortical
porosity and microfractures, osteoblastic dys-
function, and trabecular bone loss with micro-
structural deterioration and adipose tissue
proliferation in the marrow space, all of which
are hallmarks of the aging skeleton. Strikingly,
these ‘‘osteocyte-less’’ mice were resistant
to unloading-induced bone loss, providing evi-
dence for the role of osteocytes in mechano-
transduction. Thus, osteocytes represent an
attractive target for the development of diag-
nostics and therapeutics for bone diseases,
such as osteoporosis.
INTRODUCTION
The integrity of the skeletal system is maintained by a
continuous remodeling process, i.e., bone resorption by
osteoclasts followed by bone formation by osteoblasts
(Karsenty and Wagner, 2002; Parfitt, 1994). The recruit-
ment and activity of osteoclasts and osteoblasts are under
hormonal (Manolagas and Jilka, 1995; Pacifici, 1996), neu-
ronal (Ducy et al., 2000), immunological (Takayanagi et al.,
2000), and mechanical control (Burger and Klein-Nulend,
1999; Ehrlich and Lanyon, 2002). With aging, especially
after menopause in females, the balancing of activities464 Cell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc.of these two cell types fails, leading to a decline in both
the quantity and quality of bone (Raisz, 2005; Seeman
andDelmas, 2006), culminating in fragility fractures (Raisz,
2005; Riggs and Melton, 1986; Seeman, 2002). Osteopo-
rotic fractures are a serious public health issue in the aging
population and impose a major economic burden world-
wide (Sambrook and Cooper, 2006).
Osteoclasts differentiate from hematopoietic progenitor
cells in bone marrow, especially of the monocyte/macro-
phage lineage, under the stimulation of two essential cyto-
kines, macrophage colony stimulating factor (M-CSF) and
receptor activator of NF-kB ligand (RANKL), and through
the coordinated actions of nuclear transcription factors,
such as c-Fos, nuclear factor of activated T cells c1 (NF-
ATc1), and NF-kB (Teitelbaum and Ross, 2003). The gen-
eration and death of osteoclasts are also kept in check
by local and systemic negative regulators, most notably
osteoprotegerin (OPG), a decoy receptor of RANKL, and
estrogen, respectively (Boyle et al., 2003). It is hypothesized
from the perspective of bone remodeling that osteoclasts
recognize and are targeted to skeletal sites of compro-
mised mechanical integrity and initiate the bone remodel-
ing process for the purpose of generating replacement
bone with mechanical competence, although the exact
cues and underlying mechanisms that target osteoclasts
to specific sites of prospective basic multicellular units
remain elusive (Parfitt, 2002).
Osteoclastic bone resorption is followed by the recruit-
ment of osteoblasts, which derive from mesenchymal
stem cells (Harada andRodan, 2003). Osteoblasts actively
synthesize extracellular matrix, represented by type I
collagen, and mineralize it (Karsenty and Wagner, 2002).
Bone formation and resorption are not independent pro-
cesses but are in fact mutually and intimately linked in that
osteoblastic/stromal cells provide an osteoclastogenic
microenvironment through presentation of RANKL and in
that the bone formation by osteoblasts depends on the
preceding resorption by osteoclasts through the action
of a putative ‘‘coupling factor’’ (Martin and Sims, 2005).
Osteocytes, the third type of bone cell, are terminally
differentiated from osteoblasts and exist embedded in
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Osteocytes in Mechanotransductionmineralized matrix, residing individually in caves called la-
cunae (Aarden et al., 1994). Osteocytes are stellate-
shaped or dendritic cells that communicate with each
other and with osteoblasts and lining cells on the bone
surface via their prominent cell processes within tunnels
called canaliculi, thereby forming a neuron-like network
throughout the skeleton (Burger and Klein-Nulend,
1999). Although osteocytes represent the most abundant
cell type in bone, their peculiar location and inaccessibility
in mineralized matrix have hampered the cellular and
molecular analysis of osteocytes, and there have been
few osteocyte-specific markers (Franz-Odendaal et al.,
2006). A lack of established methods for isolation and
cultivation of osteocytes has imposed another obstacle,
and there have been very few cell lines available to study
osteocyte biology (Kato et al., 1997). Furthermore, even if
available, isolated osteocytes on a dishmay not behave as
osteocytes do in the complex three-dimensional structure
and environment in vivo. Our current knowledge of this
particular cell type is based mainly on observations
in vitro, and the in vivo function of osteocytes remains to
be determined. In the present study, we generated
amousemodel of osteocyte ablation that allowed elucida-
tion of the physiological function of osteocytes in bone
remodeling and mechanotransduction in an intact animal.
RESULTS
Generation of a Transgenic Mouse Model
for Inducible Ablation of Osteocytes
In order to delineate the function of osteocytes in vivo, we
attempted to establish a transgenic mouse model based
on the diphtheria toxin receptor-mediated cell knockout
(TRECK) system (Saito et al., 2001). In order to direct the
expression of diphtheria toxin receptor (DT-R) specifically
in osteocytes, we used the promoter of dentin matrix pro-
tein 1 (DMP1), which was originally identified in dentin
(George et al., 1993). In situ hybridization and immuno-
histochemical analysis with a specific antibody demon-
strated that DMP1 is highly expressed in osteocytes as
well as in dentin, but not in osteoblasts (Toyosawa et al.,
2001). A transgenic cassette (pDTR-9.6kb) carrying a ge-
nomic fragment comprised of a 9.6 kb 50-flanking region,
exon 1, intron 1, and a part of exon 2 of the mouse
DMP1 gene fused to human HB-EGF (DT-R) cDNA with
a polyadenylation signal was constructed (Figure 1A).
Transgenic DTR-9.6kb lines were produced using a stan-
dard pronuclear injection protocol and were identified
by genomic Southern hybridization and PCR (data not
shown) using the primers shown in Figure 1A. Four inde-
pendent transgenic founders were mated to wild-type
C57BL/6 mice, and the F1 offspring were analyzed. All
four lines produced pups at the expected ratio. These
pups appeared normal, grew indistinguishably from
wild-type mice, and were fertile. Two lines (#2 and #4)
showed a very similar DT sensitivity and phenotype
(data not shown), and the results presented here are
from DTR-9.6kb line #2. RT-PCR with RNAs extracted
from various tissues revealed that DT-R mRNA was ex-Cpressed only in bone and dentin of transgenic mice
(Figure 1B). Immunohistochemical analysis with a specific
antibody against DT-R (humanHB-EGF) showed that DT-R
was expressed specifically in osteocytes of trabecular
(Figure 1C) as well as cortical bone (Figure 1D), but not
in osteoblasts on the bone surface (Figure 1E).
DT-RmRNA expression in bone cells was further exam-
ined by RT-PCR. DT-R mRNA was detected only in RNA
extracted from the bone of DTR-9.6kb transgenic mice,
and not in bone of wild-type mice (see right panel of
Figure S1A in the Supplemental Data available with this
article online). On the other hand, when osteoblasts
were isolated from the calvaria of transgenic mice, DT-R
mRNA was not detected (Figure S1A, left panel), and
primary osteoblasts isolated from either transgenic or
wild-type mice did not respond to DT with cell death
(Figure S1B). Forced expression of DT-R in these osteo-
blasts by retroviral infection rendered them sensitive to
DT; prompt and massive apoptosis was observed
(Figure S1B), and all cells died within 24 hr. Collectively,
the data indicate that the 9.6 kb DMP1 promoter with
intron 1 conferred preferential expression of DT-R in
osteocytes, but not in osteoblasts.
Specific Ablation of Osteocytes in Transgenic Mice
Osteocytes normally reside individually in their lacunae
(Figures 2A and 2B), and administration of DT (up to
50 mg/kg bodyweight) to wild-typemice caused no change
in osteocyte morphology (Figure 2A, upper right panel).
DTR-9.6kb transgenic mice exhibited no overt differences
in skeletal phenotype compared with wild-type mice.
Bone histology of the transgenic mice injected with PBS
as vehicle was indistinguishable from that of wild-type
mice, and the number and morphology of osteocytes
were normal (Figure 2A, lower left panel). There was no
significant difference in cortical width (151 ± 4 mm in
wild-type versus 156 ± 3 mm in transgenic mice). In con-
trast, a number of empty lacunae that did not contain
osteocytes were observed in the cortical bone of
10-week-old male DTR-9.6kb transgenic mice at 8 days
following a single i.p. administration of DT (Figures 2A
and 2E). Empty lacunae appeared within 48 hr after DT
administration (data not shown). The counting of lacunae
in bone sections at 8 days indicated that the number of
empty lacunae increased markedly (up to 50%–60%) in
femoral cortical bone, specifically in those sections pre-
pared from transgenic mice injected with DT (Figure 2F,
red bars). Even in the lacunae that were not empty, elec-
tron microscopic examination revealed that 40% of the
osteocytes (Figure 2F, yellow bars) had undergone apo-
ptotic or necrotic changes (Figures 2C and 2D). Thus, it
was estimated that more than 70% of the osteocytes in
the cortical bone were ablated in the current transgenic
model (Figure 2F, red plus yellow bars). Successful abla-
tion of osteocytes was also confirmed in the trabecular
bone of DTR-9.6kb transgenic mice injected with DT (Fig-
ures S2A and S2B) and was also observed in vertebrae
and in both male and female mice at 8–24 weeks of age
(data not shown).ell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc. 465
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Osteocytes in MechanotransductionFigure 1. Generation of Transgenic Mice Expressing DT-R Specifically in Osteocytes
(A) Schematic representation of the transgenic construct (pDTR-9.6kb). Diphtheria toxin receptor (DT-R, dotted box) with poly(A) signals (dark box)
was placed under the control of the 9.6 kb mouse DMP1 promoter (thick line) plus exons 1 and 2 (white bars) and intron 1 between them. The arrows
indicate the set of primers used for confirming integration of the transgene (one in exon 2 of the DMP1 gene, and the other in the DT-R cDNA).
(B) RT-PCR analysis of transgene (DT-R) expression in DTR-9.6kb transgenic line #2. RNA for bone and dentin was prepared from tibiae/femurs and
incisors, respectively.
(C–E) Immunohistochemical detection of the transgene product, DT-R, by anti-DT-R (hHB-EGF) antibody in osteocytes of trabecular (C) and cortical
bone (D) of the femur of an 8-week-old transgenic mouse. (GP, growth plate; TB, trabecular bone; CB, cortical bone.) Representative osteocytes with
prominent staining are indicated by black arrows. A highmagnification of a trabecula reveals that osteoblasts on the surface do not express DT-R (red
arrows in [E]).In order to determine whether blockade of protein syn-
thesis by DT induces apoptosis of osteocytes, we exam-
ined bone tissues by the TUNEL method. Transgenic
mice injected with DT exhibited a markedly increased
number of TUNEL-positive osteocytes, but not in osteo-
blasts, at 36 hr (Figure 2G). Osteoblasts on the trabecular
bone surface appeared morphologically normal following
DT administration (Figure S2A, black arrows). Lack of DT466 Cell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Incsensitivity was further confirmed in primary osteoblasts
from the calvaria of transgenic mice. As shown in Figures
S1C and S1D, proliferation and differentiation of primary
osteoblasts from transgenic mice as assessed by BrdU
incorporation and alkaline phosphatase (ALP) activity,
respectively, were indistinguishable from those of wild-
type osteoblasts and were not influenced by DT treat-
ment ex vivo. Thus, it was concluded that 70%–80% of.
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Osteocytes in MechanotransductionFigure2. TargetedAblationofOsteocytes
in Transgenic Mice
(A) Ten-week-old male wild-type (WT, upper
panels) and transgenic (Tg, lower panels)
mice were injected i.p. with PBS (left panels)
or 50 mg/kg body weight DT (right panels),
and femoral cortical bone was stained with
hematoxylin and eosin at 8 days post DT treat-
ment. Note that empty lacunae are observed
only in cortical bone of transgenic mice in-
jected with DT (arrows). Scale bars = 50 mm.
(B–E) Osteocyte morphology by electron
microscopy showing a normal osteocyte (B),
osteocytes with nuclear condensation (C) or
fragmentation (D), and an empty lacuna (E)
from wild-type mice (B) or transgenic mice
injected with DT (C–E) at 8 days.
(F) Numbers of empty lacunae (red), lacunae
with apoptotic osteocytes (yellow), and lacu-
nae with normal osteocyte morphology (blue)
were counted in femoral cortical bone from
WT and Tg mice at 8 days following injection
of PBS or DT. Mean values are shown as a
percentage of all lacunae (n = 3–6).
(G) TUNEL staining (arrows) of femoral
sections of WT and Tg mice 36 hr after DT
administration.osteocytes had been successfully ablated in cortical as
well as trabecular bone (Figure 2F and Figure S2B, red
plus yellow bars) following a single DT administration.
Short-Term Effects of Osteocyte Ablation
The roles that osteocytes play in bone metabolism were
then investigated using the current transgenic model. At
8 days following a single i.p. administration of DT to
DTR-9.6kb mice, regions of enlarged empty lacunae
with vascular invasion (Figure 3A and inset) and invasion
of tartrate-resistant acid phosphatase (TRAP)-positive os-
teoclasts (Figure 3B) were observed in the cortical bone.
ALP staining revealed the presence of ALP-positive oste-
oblasts on the wall of the intracortical cavities excavated
by osteoclasts (Figure 3C), indicating that osteoblasts
had been recruited into the cavities alongwith the invading
osteoclasts.
von Kossa staining counterstained with toluidine blue
revealed areas that stained positively with toluidine blue
on the wall of enlarged lacunae (blue staining indicated
by white arrows in Figure 3D) and also on the endostealCsurface of the osteocyte-ablated cortical bone (blue
staining indicated by red arrows in Figure 3D) of DT-
injected transgenic mice, suggesting the development of
unmineralized matrix. The osteoid surface in the trabe-
cular bone was also increased (Figure 3F). Electron mi-
croscopy revealed the presence of microfractures in the
cortical bone following osteocyte ablation (Figure 3E,
yellow arrows). These results suggest that osteocytes
play a critical role in keeping bone resorption from under-
going aberrant acceleration and that, in the absence of
osteocytes, intra- as well as endocortical mineralization
is impaired.
Osteocyte ablation had no short-term impact on trabec-
ular bone mass; 3D bone volume at the tibial metaphysis,
as determined bymicrocomputed tomography (micro-CT)
scanning, did not differ between osteocyte-ablated mice
and controls at 1–2 weeks after DT administration
(Figure 3G and data not shown). In the trabecular bone
of osteocyte-ablated mice, however, increased TRAP
staining was observed compared with the DT-injected
wild-type mice used as a control (Figure 3H).ell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc. 467
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cyte Ablation
(A) Histological analysis of hematoxylin-and-
eosin-stained sections of femurs from 10-
week-old WT (left) and Tg (right) mice at
8 days after a single injection of DT. Note the
empty lacunae (arrows) and intracortical cavi-
ties with vascular invasion. (BV in inset, blood
vessel.)
(B–D) TRAP (B), ALP (C), and von Kossa (D)
staining of femurs of WT (left) and Tg (right)
mice injected with DT. Arrows and the asterisk
in (B) indicate empty lacunae and intracortical
cavities, respectively. The blue staining shown
by the red arrows and white arrows in (D) indi-
cates osteoid on the endosteal surface and on
the wall of intracortical cavities, respectively.
(E) The presence of microfractures (yellow ar-
rows) following osteocyte ablation as revealed
by electron microscopy. Red arrows indicate
red blood cells in the cracks. The asterisk indi-
cates an empty lacuna. Magnification 10003.
(F) Osteoid surface fraction per bone surface
(OS/BS) measured at the trabecular bone of
the proximal tibia. In this and all other figures,
error bars indicate ±SEM. *p < 0.05 (n = 5).
(G) Trabecular bone volume/tissue volume
(BV/TV) in the proximal tibia as determined by
micro-CT was unchanged at 8 days following
osteocyte ablation.
(H) TRAP staining of the trabecular bone of WT
(left) and Tg (right) mice at 8 days after DT
administration.
(I) Histomorphometric indices of bone forma-
tion in the femur at 7 days after injection of
DT or PBS in 10-week-old WT or Tg mice.
Osteoblast surface (Ob.S) and bone formation
rate (BFR) were corrected for bone surface
(BS). MAR, mineral apposition rate; Mlt, miner-
alization lag time. **p < 0.01 (n = 3 per group).Histomorphometric analysis of the trabecular compart-
ment of femurs at 8 days of osteocyte ablation revealed no
change in the number of osteoblasts (Figure 3I), suggest-
ing that differentiation/recruitment of osteoblasts was not
affected shortly after DT administration. The mineralizing
function of mature osteoblasts on trabecular bone as
assessed by the mineral apposition rate (MAR) and miner-
alization lag time (Mlt) was significantly reduced following
osteocyte ablation (Figure 3I). Taken together with the
presence of unmineralized bone matrix on the endosteal
surface and within the cortical bone of osteocyte-ablated
mice (Figure 3D), this suggests that osteocytes play an
important role in maintaining the mineralizing function of
mature osteoblasts.
Bone-marrow cells were isolated from femurs and tibiae
of wild-type as well as transgenic mice treated in vivo with
DT or PBS, and ex vivo colony-formation assays were
performed (Figure S3). FACS analysis revealed that the468 Cell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Innumber of total bone-marrow cells and major cell popula-
tions did not differ among the four experimental groups,
except for a modest decrease in B220-positive B lineage
cells in the DT-injected transgenic mice (data not shown).
The results of the colony-formation assays revealed that
the number of cfu-F, cfu-ALP, and cfu-OB did not differ
between the wild-type and transgenic-derived cultures
or between cultures of PBS-injected and DT-injected
transgenic mice (Figure S3), suggesting that osteoblast
differentiation was not affected by osteocyte ablation.
Osteocyte Ablation Increases the RANKL/OPG Ratio
Quantitative RT-PCR using RNA samples extracted from
bone of transgenic mice treated with DT revealed that
the expression of DT-R (human HB-EGF) mRNA as well
as DMP1 mRNA decreased markedly at 2 days following
DT injection in DTR-9.6kb transgenic mice (Figure 4),
which documents successful osteocyte ablation at thec.
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Osteocytes in MechanotransductionFigure 4. Quantitative RT-PCR Analysis
of Molecular Markers of Bone Cells
After the bone marrow had been flushed out,
RNA was extracted from the femurs and tibiae
of 10-week-old DTR-9.6kb transgenic mice
injected with PBS (white bars) or DT (black bars)
at 2 days. Gene expression was assessed by
real-time PCR using a LightCycler system
and normalized to EF-1amRNA.MEPE, matrix
extracellular phosphoglycoprotein; Phex,
phosphate-regulating gene with homologies
to endopeptidases on the X chromosome;
RANKL, receptor activator of NF-kB ligand;
OPG, osteoprotegerin; ALP, alkaline phospha-
tase;OC, osteocalcin. **p < 0.01; *p < 0.05 (n =
3 mice per group).molecular level. Reduction in DT-R mRNA reached nearly
100%, pointing to nearly complete ablation of osteocytes
that expressed DT-R. TheDMP1mRNA level was reduced
by approximately 70%, consistent with the histological
observations that 70%–80% of osteocytes were ablated,
provided that all osteocytes expressed DMP1 mRNA.
mRNA expression of FGF-23, sclerostin, MEPE, Phex,
and E11/gp38, known products of osteocytes (Franz-
Odendaal et al., 2006), also decreased significantly follow-
ing osteocyte ablation (Figure 4).
Among the molecules involved in bone resorption,
mRNA for RANKL increased; mRNA for OPG was un-
changed at 2 days (Figure 4) but decreased modestly at
4 days (data not shown). Interestingly, ex vivo cultures of
bone-marrow cells from osteocyte-ablated mice under
osteogenic conditions gave rise to TRAP-positive osteo-
clast-likecells inassociationwithALP-positiveosteoblastic
colonies even without the addition of any stimulator of
osteoclastogenesis, suchasRANKL,whereas the formation
of osteoclasts on osteoblastic colonies occurred much
less frequently in cultures from control mice (Figure S4).
With regard to the molecular markers of osteoblast dif-
ferentiation, osteocalcin mRNA level decreased, whereas
levels of Runx2 (Karsenty and Wagner, 2002) and Osterix
(Nakashima et al., 2002) as well as ALP mRNA remained
unaltered (Figure 4 and data not shown). Thus, following
the ablation of osteocytes, the impaired transcription
function of Runx2 without a change in gene expression
per se is thought to lead to the reduced expression of
the osteocalcin gene.
Longer-Term Consequences of Osteocyte
Deficiency
Histological examination of tibiae at 40 days following
a single injection of DT revealed that empty lacunae stillCexisted and that cortical bone became thin as compared
with bone of DT-injected wild-type mice (Figure 5A). The
cortical area of the femurwas decreased (data not shown),
and intracortical porosity was markedly increased in the
osteocyte-ablated mice (Figures 5B and 5C). In fact,
bone strength, as determined by the four-point bending
test, was significantly compromised 40 days following
osteocyte ablation (Figure 5H). These results suggest
that the presence of osteocytes is critical for the mainte-
nance of structural integrity and mechanical competence
of cortical bone.
Histological examination of the tibial metaphysis 40 days
after a single injection of DT revealed that the trabecular
bone had become thin and sparse, with an expansion of
adipose tissue in the marrow space, as compared with
bone of DT-injected wild-type mice (Figures 5A and 5D).
Not only appendicular bone but also axial bone displayed
substantial structural changes 40 days after osteocyte
ablation. Micro-CT scanning of the lumbar vertebrae
revealed a substantial decrease in the 3D trabecular
bone volume per tissue volume (BV/TV) (Figures 5E and
5F). This decrease was associated with microstructural
changes in the trabeculae, represented by decreased
trabecular connectivity, reduced trabecular thickness,
and an increased structure model index (SMI), implying
transformation of the trabeculae from plate-like structures
to more fragile rod-like ones (Figure 5F). These results
indicate that the long-term consequences of osteocyte
ablation result in a loss of trabecular bone mass with
ensuing microarchitectural deterioration.
In order to follow up on the recovery process after a tran-
sient ablation of osteocytes, a cohort of transgenic as well
as wild-type mice were treated with DT, and tibial trabec-
ular bone was analyzed by micro-CT at 40 days and then
90 days post DT administration, when normal osteocytesell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc. 469
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bone volume was restored to a level indistinguishable
from the control group at 90 days following DT administra-
tion (Figure 5G). Accordingly, bone strength was also re-
stored to the control level at 90 days (Figure 5H). Thus, it
is suggested that the bone loss and compromised
strength following osteocyte ablation are reversible and
Figure 5. Osteoporotic Changes as Long-Term Conse-
quences of Osteocyte Ablation
(A and B) Representative tibial sections of 18-week-old WT and Tg
mice at 40 days following a single DT administration. Note the thinning
of the cortical bone and accumulation of adipose tissue in the marrow
space following osteocyte ablation. Scale bars = 200 mm. Part of the
cortical bone in (A) is highlighted in (B) to illustrate intracortical porosity
(arrows).
(C and D) Intracortical porosity area per cortical area (Po.Ar/Ct.Ar) (C)
and marrow adiposity (% fat volume/marrow volume) (D) of femurs at
40 days after DT administration. **p < 0.01 (n = 5–6 per group).
(E and F) Representative micro-CT images of lumbar vertebrae of WT
and Tgmice at 40 days following DT administration (E) withmicrostruc-
tural parameters (BV/TV, 3D bone volume fraction per tissue volume;
Conn-Dens., connectivity density; SMI, structure model index;
Tb.Th, trabecular thickness) derived from micro-CT analysis (F). **p <
0.01 (n = 5 per group).
(G and H) Recovery of bone volume (G) and bone strength (H) along
with osteocyte regeneration. Trabecular bone volume and bone
strength were determined by micro-CT and the four-point bending
test, respectively, on the femurs of transgenic mice injected with
PBS (white bars) or DT (black bars) at 40 and 90 days. *p < 0.05;
**p < 0.01 (n = 5 per group).470 Cell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc.that the quantity and quality of bone are normalized
as new osteocytes differentiate from osteoblasts and
become embedded in the skeleton.
Osteocytes in Mechanotransduction
Transgenic micewith inducible osteocyte ablation provide
an ideal model to determine the role of osteocytes in me-
chanotransduction in an intact animal. DTR-9.6kb trans-
genic mice as well as wild-type controls were subjected
to unloading by tail suspension for 7 days (Bikle and
Halloran, 1999; Globus et al., 1984); DT was administered
1 day prior to the initiation of tail suspension to deplete
osteocytes (Figure 6A). Mice on the ground under normal
loading conditions during the same period served as con-
trols. Note that during a short period of 1 week following
DT administration, trabecular bone volume did not differ
between the wild-type and transgenic mice on the ground
(Figures 6A and 6B), as previously observed in separate
experiments (Figure 3G). As expected, wild-type mice in-
jected with DT as well as transgenic mice injected with
PBS lost a substantial portion of trabecular bone during
the 1 week tail suspension (Figures 6A and 6B). Strikingly,
transgenic mice injected with DT and therefore rendered
osteocyte deficient were resistant to unloading-induced
bone loss (Figures 6A and 6B), which provides in vivo
evidence that the presence of osteocytes is crucial for
mechanotransduction in bone. The microarchitectural
deterioration induced by unloading, as demonstrated by
micro-CT scanning, was also completely inhibited in the
osteocyte-ablated mice (Figure S5).
Histomorphometric analysis revealed that the increase
in osteoclast number observed in control mice during me-
chanical unloading as well as suppressed bone formation
was abrogated in osteocyte-ablated mice (Figure 6C).
When RNA extracted from tibiae and femurs at 1, 2, and
3 days after the initiation of tail suspension was analyzed
by quantitative RT-PCR, RANKL mRNA increased within
1–2 days compared to control and increased progres-
sively thereafter at 3 days, with a slightly delayed increase
in OPG mRNA at 3 days in the wild-type mice (data not
shown). In osteocyte-ablated mice, the increases in
RANKL and OPG mRNA during tail suspension were
blocked (Figure 6D), suggesting that the increase in
RANKL expression in osteoblasts in response to mechan-
ical unloading does not take place in the absence of
osteocytes, which may underlie the resistance to disuse-
induced bone loss. sclerostin mRNA increased during
tail suspension, a result thatwas not observed in osteocyte-
ablated mice (Figure 6D).
In order to examine the role of osteocytes in reloading,
following the completion of tail suspension for 7 days,
we injected either DT or PBS into DTR-9.6kb trans-
genic mice and left them ambulatory for the subsequent
14 days (Figure 7A, groups 4 and 3, respectively). The lim-
iting of osteocyte ablation to the reloading period did not
affect the robust recovery of bone mass, and osteocyte-
deficient mice gained an amount of bone similar to
PBS-injected control mice (Figures 7A and 7B). Bone
histomorphometry revealed that the increased osteoclast
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Osteocytes in MechanotransductionFigure 6. Osteocyte-Ablated Mice Are Resistant to Unloading-Induced Bone Loss
(A) Experimental schedule with representative micro-CT images. Eighteen-week-old WT and Tg mice were subjected to skeletal unloading by tail
suspension (TS) for 7 days. Mice on the ground (Gr) served as controls. DT was administered 1 day prior to the initiation of TS (1).
(B) Changes in 3D bone volume at the tibial metaphysis following 7 day unloading by tail suspension (black bars). Mice on the ground (white bars)
served as controls. **p < 0.01 (n = 5 per group).
(C) Number of osteoclasts (N.Oc/BS) and bone formation rate (BFR/BS) in TS (black bars) and ground control (white bars) mice. *p < 0.05 (n = 5 per
group).
(D) Quantitative RT-PCR analysis. RNA was extracted from tibiae and femurs of WT and DTR-9.6kb Tg mice injected with DT (red bars) or PBS (pale
green bars) at 3 days following the initiation of TS, after bone marrow had been flushed out. Transgenic mice on the ground (Gr) served as controls
(white and black bars). *p < 0.05; **p < 0.01 (n = 3 per group).number following tail suspension as well as suppressed
bone formation was normalized during the reloading
period in osteocyte-ablated mice to the same extent as
in the control mice (Figure 7C). These results indicate
that osteocytes are indispensable for unloading-induced
bone loss, while recovery by reloading can bypass
osteocytes (Figure 7D).
DISCUSSION
In this study, we have established a mouse model for the
inducible ablation of osteocytes, which has allowed delin-
eation of crucial functions in skeletal homeostasis in vivo.
We have demonstrated that osteocytes play an important
role in the regulation of osteoblastic and osteoclastic
activities on the bone surface and have provided proof
for the essential function of osteocytes in mechanotrans-Cduction in vivo. Despite the fact that 70%–80%, not
100%, of osteocytes were ablated, transgenic mice
injected with DT exhibited marked alterations in bone
metabolism, which may be explained by osteocytes func-
tioning as a network, such that 70%–80% ablation is
sufficient to cause a serious malfunction of the network
as a whole.
We have achieved specific ablation of osteocytes in
a transgenic model by targeting DT-R to osteocytes under
the control of the DMP1 promoter. DMP1 was originally
identified in dentin and encodes an extracellular-matrix-
associated phosphoprotein (George et al., 1993). While
the reported phenotypes of DMP1 knockout mice in
bone mineralization (Feng et al., 2006; Ling et al., 2005)
and chondrogenesis (Ye et al., 2005) suggest that DMP1
serves physiological functions in osteoblasts and chon-
drocytes, the transgenic approach that we and othersell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc. 471
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Osteocytes in MechanotransductionFigure 7. Absence of Osteocytes Does Not Affect Bone Gain during Reloading
(A) Experimental schedule for reloading after tail suspension (TS/Gr) and representative micro-CT images. Eighteen-week-old WT and DTR-9.6kb
Tg mice were subjected to TS for 7 days and were then left ambulatory for the following 14 days. DT (4) or PBS as vehicle (3) was injected before
initiation of reloading so that osteocytes were ablated specifically during the reloading period (4). Mice on the ground throughout the experimental
period (1) and mice subjected to TS only (2) served as controls.
(B and C) Changes in 3D bone volume at the tibial metaphysis of WT and Tgmice with or without DT administration (B) and histomorphometric indices
for osteoclast number (N.Oc) and bone formation rate (BFR) corrected for bone surface (BS) (C) after reloading (TS/Gr). **p < 0.01; *p < 0.05 (n = 5 per
group). (1)–(4) correspond to the four experimental groups shown in (A).
(D) Proposed roles of osteocytes under different mechanical conditions. Based on the current results, under normal loading conditions (Mechanical
input +), osteocytes function to keep osteoclastic (Oc) bone resorption in check and to maintain mineralization by osteoblasts (Ob). Thus, when os-
teocytes are ablated, aberrantly elevated bone resorption with impaired mineralization takes place. In response to unloading (Mechanical input ),
osteocytes execute the stimulation of bone resorption and suppression of bone formation, resulting in marked bone loss and microstructural dete-
rioration in a short period. Thus, when osteocytes are ablated specifically during tail suspension, those changes do not take place, and bone is
resistant to disuse-induced atrophy. However, based on the results of the reloading experiments following unloading (Mechanical input / +), it
is suggested that osteocytes are dispensable for this recovery phase and that osteoclasts (Oc) and osteoblasts (Ob) respond to the reloading
stimulus, bypassing osteocytes, with reversal of elevated bone resorption and release from suppressed bone formation, respectively.(Kalajzic et al., 2004; Yang et al., 2005) employed with a
relatively long promoter conferred selective expression
of DT-R in osteocytes.
In addition to immunohistochemical and RT-PCR anal-
yses, we confirmed specific expression of DT-R in osteo-
cytes in several functional assays. First, treatment ex vivo
of transgenically derived osteoblasts with DT did not472 Cell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Incinduce cell death, whereas osteoblasts isolated in the
same manner and transduced ex vivo with DT-R by
retroviral infection responded promptly with cell death.
Second, bone histomorphometric analysis shortly after
DT administration to transgenic mice revealed no change
in the number of osteoblasts compared with control mice.
Third, bone-marrow cultures from transgenic mice treated.
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ALP, and cfu-OB as cultures from wild-type mice in col-
ony-formation assays. Finally, when primary osteoblasts
isolated from transgenic mice were treated with DT, their
proliferation and differentiation as determined by BrdU in-
corporation and ALP activity, respectively, were not af-
fected and were indistinguishable from wild-type osteo-
blasts. Taken together, these results indicate that DT-R
was targeted specifically to osteocytes, and not to osteo-
blasts.
Bone remodeling is performed by effector cells at the
bone surface, i.e., osteoclasts and osteoblasts. We have
demonstrated that osteocytes deep inside the bone serve
an important function in regulating the activities of osteo-
clasts and osteoblasts at the bone surface and that deple-
tion of osteocytes impairs bone homeostasis through
altered activities of osteoclasts and osteoblasts. The re-
sults of gene expression analysis suggest that osteocytes
control osteoclast differentiation indirectly through modu-
lation of RANKL expression in osteoblasts. Since osteo-
cytes make direct contact with osteoblasts and lining cells
on the bone surface through gap junctions (Aarden et al.,
1994), it is plausible to assume that cell-cell contact
between osteocytes and osteoblasts normally restrains
RANKL gene expression from aberrant activation, while
osteocyte ablation or disruption of the osteocyte network
releases this negative regulation, resulting in aberrantly el-
evated RANKL expression and osteoclastogenesis. Small
molecules passing fromosteocytes to osteoblasts through
gap junctions may be involved in the regulation of RANKL
expression in osteoblasts. Alternatively, as osteocytes
extend cell processes into the marrow space (Kamioka
et al., 2001), humoral factors produced by osteocytes
and released through canaliculi into the bone marrow
may regulate the differentiation and activity of osteoclasts.
The data suggest that osteocytes are also involved in
the mineralizing function of mature osteoblasts in associ-
ation with reduced expression of the osteocalcin gene.
Sclerostin, the product of the SOST gene, is secreted
from osteocytes (Poole et al., 2005) and negatively regu-
lates osteoblastic bone formation by antagonizing BMP
and Wnt signals (Li et al., 2005; van Bezooijen et al.,
2004; Winkler et al., 2003), making it a likely candidate
as an osteocyte-derived regulator of osteoblastic func-
tion. Since the expression of sclerostin mRNA decreased
markedly following osteocyte ablation in the current
model, which would cause stimulation of bone formation,
it is conceivable that in addition to negative regulators
such as sclerostin, one or more positive regulators are
produced by osteocytes tomaintain themineralizing func-
tion of osteoblasts. The expression of DMP1 and FGF-23,
osteocyte-derived factors that regulate mineralization and
phosphate homeostasis (Feng et al., 2006; Liu et al., 2006;
Shimada et al., 2004), was reduced together with that of
other markers of osteocytes, such as MEPE, Phex, and
E11/gp38 (Franz-Odendaal et al., 2006). Following osteo-
cyte depletion, however, there were no alterations in the
systemic calcium or phosphate concentrations (data not
shown). Further studies are required to identify osteocyteCproducts that regulate osteoblastic as well as osteoclastic
activities.
Although it is widely believed that the osteocyte network
serves a mechanosensory function (Aarden et al., 1994;
Burger and Klein-Nulend, 1999), direct proof for this
hypothesis in the intact animal has not been obtained.
Osteocyte-ablated mice exhibited almost complete resis-
tance to bone loss induced by tail suspension, which was
associated with an absence of any increase in osteoclas-
tic bone resorption in response to unloading. These re-
sults indicate that osteocytes play a crucial role in sensing
the local changes inmechanical strains evoked by unload-
ing and/or play a role in transmitting pro-osteoclastogenic
signals to stimulate bone resorption in response to me-
chanical unloading (Figure 7D). Taken together with the
accelerated bone resorption and elevatedRANKL expres-
sion following osteocyte ablation under ambulatory (i.e.,
normal loading) conditions, this suggests that osteocytes
transduce opposite signals, an anti-osteoclastogenic sig-
nal (under normal loading) versus a pro-osteoclastogenic
signal (in response to unloading), depending on the nature
and direction of mechanical inputs (Figure 7D).
Osteoporosis has been viewed as a disease encom-
passing osteoclasts and osteoblasts, in which the bone-
resorbing activity of the former exceeds the bone-forming
ability of the latter, and its treatment as well as diagnosis
has been directed toward these two major cell types. It
has been reported that osteocyte density declines with
aging (Qiu et al., 2002), and osteocyte apoptosis has
been documented in estrogen deficiency (Tomkinson
et al., 1997) and glucocorticoid treatment (Weinstein
et al., 2000). The findings that the loss of osteocytes re-
sults in not only reduced bone mass but compromised
bone quality with trabecular microstructural alterations,
intracortical porosity, and microfractures suggest that os-
teocyte deficiency/malfunction may underlie bone fragility
under various conditions (Seeman andDelmas, 2006), and
that osteocytes therefore comprise an important target for
the development of diagnostics and therapeutics for bone
disease, as exemplified by osteoporosis.
EXPERIMENTAL PROCEDURES
Reagents
Diphtheria toxin was purchased from Sigma and dissolved in PBS.
Polyclonal goat anti-DT-R (hHB-EGF) antibody was obtained from
Genzyme-Techne.
Generation of Transgenic Mice and Animal Experiments
A transgenic cassette carrying a genomic fragment comprised of the
9.6 kb 50-flanking region, exon 1, intron 1, and a part of exon 2 of the
mouse DMP1 gene fused to human HB-EGF (DT-R) cDNA with a poly-
adenylation signal was constructed. Founder mice were generated by
microinjection of the DNA into fertilized eggs of C57BL/6mice. Integra-
tion of the transgene was confirmed by Southern and PCR analyses of
genomic DNA extracted from the tail.
Mice were raised under standard laboratory conditions at 24C ±
2C and 50%–60% humidity and were allowed free access to tap wa-
ter and commercial standard rodent chow (CE-2) containing 1.20%
calcium, 1.08% phosphate, and 240 IU/100 g vitamin D3 (Clea Japan
Inc.). Transgenic mice were injected i.p. with 2–50 mg/kg body weightell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc. 473
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for 7 days, followed by reloading for 14 days, as described previously
(Globus et al., 1984; Sessions et al., 1989). All experiments were
performed in accordance with National Center for Geriatrics and
Gerontology’s ethical guidelines for animal care, and the experimental
protocols were approved by the animal care committee.
Cell Culture and Gene Expression Studies
Bone-marrow cells were prepared from C57BL/6 mice and cultured in
aMEMmedium supplemented with 10% FCS as described (Takeshita
et al., 2002). Retroviral vectors encoding DT-R were used to transfect
Plat-E retrovirus packaging cells (a gift from T. Kitamura, University of
Tokyo). Primary calvarial osteoblasts were infected with the retroviral
vector pMX-puro expressing DT-R under the control of Mo-MLV
LTR, cultured in the presence of polybrene (4 mg/ml) for 1 day, and
then treated with DT in the presence of puromycin (1.6 mg/ml). Apopto-
sis of osteoblasts was assessed using a Cell Death Detection ELISA
kit (Roche Diagnostics). Osteoclast differentiation was evaluated as
described previously (Takeshita et al., 2002).
Total RNA was isolated from bone with TRIzol Reagent (Invitrogen).
Tissue distribution of DT-R was analyzed by RT-PCR with the
primer set 50-TCGAGAACTTCGCTGAGG-30 and 50-CGCCAGTCAC
CAGTGCCGAG-30 at 94C for 30 s, 55C for 1 min, 72C for 1 min
for 35 cycles.
For quantitative RT-PCR, total RNA (1 mg) was reverse transcribed
using SuperScript III (Invitrogen), and samples were analyzed using
a LightCycler system (Roche Diagnostics). The primers included 50-
GGCTGTCCTGTGCTCTCCCAG-30 and 50-GGTCACTATTTGCCTGT
GCCTC-30 for DMP1, 50-ACTTGTCGCAGAAGCATC-30 and 50-GTGG
GCGAACAGTGTAGAA-30 for FGF-23, 50-CTTCAGGAATGATGCCAC
AGAGGT-30 and 50-ATCTTTGGCGTCATAGGGATGGTG-30 for sclero-
stin, 50-AGGACCCAAGGGCAAGAG-30 and 50-TGTCTTCATTCGGCA
TTGG-30 for MEPE, 50-GTGCATCTACCAACCAGATACG-30 and 50-
TCTGTTCCCCAAAAGAAAGG-30 for Phex, 50-CAGTGTTGTTCTGGG
TTTTGG-30 and 50-TGGGGTCACAATATCATCTTCA-30 for E11/gp38,
50-TGGAAGGCTCATGGTTGGAT-30 and 50-CATTGATGGTGAGGTGT
GCAA-30 for RANKL, 50-CTTGCCTTGATGGAGAGCCT-30 and 50-
TCGCTCGATTTGCAGGTCT-30 for OPG, 50-CACTGCCACCTCTGA
CTTCT-30 and 50-GCTCTCAGTGAGGGATGAAA-30 for Runx2, 50-
CAGGGTACACCATGATCTCACC-30 and 50-CGCCCATACCATCTCC
CAGG-30 for ALP, 50 GAGGACCATCTTTCTGCTCAC-30 and 50-CCA
AGGTAGCGCCGGAGTCTG-30 for osteocalcin, and 50-TGCTGCCA
TTGTTGATATGG-30 and 50-TCCACAGCTTTGATGACACC-30 for
EF-1a. The amount of target mRNA was normalized to EF-1a mRNA.
Bone Analysis
Eight- to eighteen-week-old transgenic mice and their wild-type litter-
mates were perfused with 4% paraformaldehyde in 0.1 M cacodylate
buffer (pH 7.4). Femurs and tibiae were immersed in the same fixative
for 12 hr prior to decalcification with 10% EDTA (pH 7.4) for 2 weeks.
These specimens were embedded in paraffin and subjected to histo-
chemistry for TRAP and ALP, as described previously (Amizuka
et al., 1999). The other specimens were postfixed with a mixture of
1% osmium tetroxide and 1.5% potassium ferrocyanide for 4 hr and
dehydrated and embedded in epoxy resin (Taab). Femoral and tibial
sections were employed for von Kossa staining and electron micros-
copy examinations (Hitachi H-7000, Hitachi Co. Ltd.), respectively.
Immunohistochemical analysis was performed on decalcified sections
by using commercially available antibodies.
Microcomputed tomography scanning was performed on proximal
tibiae and lumbar vertebrae using mCT-40 (SCANCO Medical AG)
with a resolution of 12 mm, and microstructure parameters were calcu-
lated three-dimensionally as described previously (Ito et al., 2005).
Bone histomorphometry was performed on undecalcified sections
with tetracycline and calcein double labeling. Histomorphometric
parameters were measured at the Ito Bone Science Institute. Bone
strength was evaluated at the femur by using the four-point bending
test (Brodt et al., 1999).474 Cell Metabolism 5, 464–475, June 2007 ª2007 Elsevier Inc.Statistical Analysis
Data are expressed as the mean ± SEM. Statistical analysis was per-
formed by unpaired Student’s t test or ANOVA followed by Dunnett’s
test or the Student-Newman-Keuls test. Values were considered
statistically significant at p < 0.05.
Supplemental Data
Supplemental Data include five figures and can be found with this ar-
ticle online at http://www.cellmetabolism.org/cgi/content/full/5/6/464/
DC1/.
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